Physician profile
Richard Zelner
NPI 1235274259
$1,633.98
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $504 · 2021: $329.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,014.87 | 2019-2021 | |
| Gilead Sciences, INC. | $284.06 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.18 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $80.89 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $30.62 | 2019 | |
| Abbvie INC. | $28.57 | 2021 | |
| Alfasigma USA, INC. | $23.38 | 2020 | |
| Shire North American Group INC | $22.76 | 2019 | |
| Redhill Biopharma INC. | $21.80 | 2020 | |
| Daiichi Sankyo INC. | $15.43 | 2019 | |
| Allergan, INC. | $14.18 | 2019 | |
| Braintree Laboratories, INC. | $13.24 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Zelner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.